Rivernorth Capital Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Rivernorth Capital Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75,650	Closed	-$758K	–	796
2022 Q3	$758K	Hold	75,650	–	–	0.03%	422
2022 Q2	$759K	Hold	75,650	–	–	0.03%	406
2022 Q1	$747K	Buy	+75,650	New	+$750K	0.03%	426
2021 Q1	–	Sell	-100,000	Closed	-$1.07M	–	516
2020 Q4	$1.07M	Buy	+100,000	New	+$1.02M	0.06%	181

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rivernorth Capital Management's EUCRU Position: Q4 2022 in Review

Rivernorth Capital Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 75,650 shares — an estimated $758K sold.

Rivernorth Capital Management first reported a position in EUCRU in Q4 2020 and held it in 4 quarters. The position peaked at $1.07M in Q4 2020. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

Rivernorth Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Rivernorth Capital Management sold 75,650 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $758K.
Rivernorth Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 4 quarters.
Rivernorth Capital Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $1.07M in Q4 2020.
6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Rivernorth Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.